MedTrace Logo

Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC

NCT03769805 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2019-10-22

No results posted yet for this study

Summary

Based on the need of clinical practice of maintenance therapy for advanced NSCLC and the reliable data of third-line treatment for non-small cell lung cancer, the investigators designed a clinical study of antinil hydrochloride versus pemetrexed in maintenance therapy for advanced NSCLC to prospectively evaluate the efficacy of antinil hydrochloride in maintenance therapy for advanced NSCLC. Value, to provide a scientific basis for prolonging the survival time of patients with advanced NSCLC, improving the quality of life of patients in the course of treatment, and optimizing treatment strategies to a greater extent.

Conditions

  • Nonsmall Cell Lung Cancer

Interventions

DRUG

Anlotinib

Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week.

Sponsors & Collaborators

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    collaborator OTHER

  • Huai'an First People's Hospital

    collaborator OTHER

  • Jiangsu Taizhou People's Hospital

    collaborator OTHER

  • Zhongda Hospital

    collaborator OTHER

  • Yancheng City NO.1 People's Hospital

    collaborator UNKNOWN

  • The Affiliated Hospital of Xuzhou Medical University

    collaborator OTHER

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Principal Investigators

  • Yongqian Shu, professor · JANGSU PROVINCE HOSPITAL

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-15
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03769805 on ClinicalTrials.gov